DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it ...
DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...
SHANGHAI, CHINA - JANUARY 25, 2022 - A 3M logo display of air-condensed thermal materials in a shopping mall in Shanghai, China, January 25, 2022. (Photo credit should read Wang Gang / Costfoto/Future ...
DexCom's Q3 performance shows impressive organic growth rates and increased revenue guidance for 2023. The company's strategic focus on international markets and expanding customer bases indicates ...
Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the trades showed up on publicly available ...
DexCom seems to be growing fairly consistently, and that could continue. But the competition for its segment is getting fiercer by the quarter. The long-term effect of new medicines could potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback